AZD 5069

Drug Profile

AZD 5069

Alternative Names: AZD-5069

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; MedImmune
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Head and neck cancer; Solid tumours
  • Phase I/II Pancreatic cancer
  • Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Dec 2016 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Italy, Spain, United Kingdom, USA (unspecified route)
  • 10 Oct 2016 Early safety and efficacy results from the phase Ib/IIa (SCORES) were presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 02 Mar 2016 AstraZeneca plans to initiate a phase II trail for Coronary disorders in United Kingdom (ISRCTN48328178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top